Mathilde Cancel

Efficacy of Savolitinib vs Sunitinib in Patients With<i>MET</i>-Driven Papillary Renal Cell Carcinoma

Toni K. Choueiri, Daniel Y.C. Heng, Jae‐Lyun Lee et al. · JAMA Oncology · 2020 · 179 citations · Full text

Medicine, Oncology, Pharmacology +13

Recurrent <i>PRKAR1A</i> Mutation in Acrodysostosis with Hormone Resistance

Agnès Linglart, Alain Couvineau, Colette Auzan et al. · New England Journal of Medicine · 2011 · 178 citations · Full text

Medicine, Endocrinology, Genetics +14

Nivolumab, nivolumab–ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial

Yann Vano, Réza Elaidi, Mostefa Bennamoun et al. · The Lancet Oncology · 2022 · 136 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Pembrolizumab in patients with rare and ultra-rare sarcomas (AcSé Pembrolizumab): analysis of a subgroup from a non-randomised, open-label, phase 2, basket trial

Jean‐Yves Blay, Sylvie Chevret, Axel Le Cesne et al. · The Lancet Oncology · 2023 · 88 citations

Medicine, Oncology, Pharmacotherapy +10

Effects of in vivo static compressive loading on aggrecan and type II and X collagens in the rat growth plate extracellular matrix

Mathilde Cancel, Guy Grimard, Delphine Thuillard-Crisinel et al. · Bone · 2008 · 68 citations

Engineering, Bioengineering, Biomedical Engineering +17